Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?

Filip IonescuChristopher CooperIoana PetrescuJulie GeorgeSaima Mansuri

Published in: European journal of haematology (2021)

Apixaban is associated with less bleeding in HD patients compared to warfarin, but concomitant antiplatelet use may negate the safety advantage. Prospective trials are warranted to determine the impact of antiplatelets on apixaban safety.

Keyphrases

atrial fibrillation
venous thromboembolism
direct oral anticoagulants
end stage renal disease
ejection fraction
peritoneal dialysis
prognostic factors
patient reported outcomes
patient reported